Jubilant Pharmova Ltd. Jubilant Pharmova
Jubilant Pharmova
Jubilant Pharmova Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
| Ex-Date | Purpose |
|---|---|
04-06-2021 | Final Dividend & Audited Results |
23-07-2021 | Quarterly Results |
22-10-2021 | Quarterly Results |
04-02-2022 | Quarterly Results |
27-05-2022 | Final Dividend & Audited Results |
02-08-2022 | Quarterly Results |
21-10-2022 | Quarterly Results |
03-02-2023 | Quarterly Results |
29-05-2023 | Final Dividend & Audited Results |
19-07-2023 | Quarterly Results |
27-10-2023 | Quarterly Results |
02-02-2024 | Quarterly Results |
25-10-2024 | Quarterly Results |
31-01-2025 | Quarterly Results |
16-05-2025 | Audited Results & Final Dividend |
29-07-2025 | Quarterly Results |
31-10-2025 | Quarterly Results |
06-02-2026 | Quarterly Results |
22-05-2026 | Audited Results & Final Dividend |
07-08-2026 | Quarterly Results |
10-08-2026 | Quarterly Results |
12-10-2026 | Inter alia, to consider and approve raising of funds through the issuance of NonConvertible Debentures (NCDs) and/or such other securities as may be permitted under applicable laws, and to approve seeking shareholders approval, as may be required in this regard. |
13-11-2026 | Quarterly Results |
News
Abakkus Asset Managers buys 0.69% stake in Jubilant Pharmova
Abakkus Four2Eight Opportunities Fund has bought 11 lakh shares of the company for around Rs 100.65 crore
Jubilant Pharmova rises on getting nod to raise up to Rs 800 crore via NCDs
The Board of Directors of the Company, at its meeting held on October 12, 2026, has, inter alia, considered and approved the same
Jubilant Pharmova gets nod to raise up to Rs 800 crore via NCDs
The Board of Directors of the Company, at its meeting held on October 12, 2026, has, inter alia, considered and approved the same
Jubilant Pharmova’s arm to invest 94.5 million Canadian Dollar to double RUBY-FILL capacity
The Government of Canada will provide a financial support of 23.8 million Canadian Dollar to this project
Jubilant Pharmova jumps on getting USFDA’s approval for new Isolator based fill and finish line at Spokane Facility
Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma, Singapore, a wholly owned subsidiary of the company
Jubilant Pharmova gets USFDA’s approval for new Isolator based fill and finish line at Spokane Facility
Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma, Singapore, a wholly owned subsidiary of the company
Jubilant Pharmova reports Profit after tax of Rs 73.00 Mln, in the June 2026 quarter
Jubilant Pharmova informs about compliances-certificate
USFDA concludes inspection at Jubilant Pharmova’s arm’s facility in U.S.A
JHS will respond to the inspection observations within 15 business days
Jubilant Pharmova informs about completion of USFDA inspection
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova reports Profit after tax of Rs 572.00 Mln, in the March 2026 quarter
Jubilant Pharmova informs about board meeting
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova reports Profit after tax of Rs 66.00 Mln, in the December 2025 quarter
Jubilant Pharmova’s arm makes investment in Jubilant Pharmaceuticals
This investment aims to establish branded Generic business in Canada and strengthening Jubilant presence in the Canadian market
Jubilant Pharmova informs about appointment of CEO
Jubilant Pharmova’s arm gets 9 observations for Canada facility after USFDA audit
JHSGP will submit an action plan on the observations
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova informs about outcome of board meeting
Jubilant Pharmova reports Profit after tax of Rs -480.00 Mln, in the September 2025 quarter
Jubilant Pharmova soars as its arm launches New Sterile Fill & Finish line at facility in US
The launch plays a key role in Jubilant HollisterStier’s multi-phase expansion strategy and brings an additional 50% capacity at its Spokane manufacturing facility
Jubilant Pharmova’s arm launches New Sterile Fill & Finish line at facility in US
The launch plays a key role in Jubilant HollisterStier’s multi-phase expansion strategy and brings an additional 50% capacity at its Spokane manufacturing facility
Jubilant Pharmova informs about press release
USFDA completes PADE inspection of Jubilant Pharmova’s arm
The inspection closed with no observations
Jubilant Pharmova gains on completing transfer of API business to Jubilant Biosys
The company had received approval from board of directors of the company on June 12, 2025 for the same
Jubilant Pharmova completes transfer of API business to Jubilant Biosys
The company had received approval from board of directors of the company on June 12, 2025 for the same
USFDA concludes PAI at Jubilant Pharmova’s arm’s facility at Roorkee
The USFDA has issued 4 observations pursuant to the completion of audit
Jubilant Pharmova informs about communication
Jubilant Pharmova informs about newspaper publication
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova reports Profit after tax of Rs 41.00 Mln, in the June 2025 quarter
Jubilant Pharmova gets nod to sell, transfer API business to Jubilant Biosys
The board of directors of the company in their meeting held on June 12, 2025 has approved the same
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova reports Profit after tax of Rs 136.00 Mln, in the March 2025 quarter
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova’s arm inks Shareholders’ Agreement with Pierre Fabre SA
The name of JASMIN has been changed to ‘Jubilant Biosys France’ which is now a subsidiary of JBIRSPL
Jubilant Pharmova trades higher on the BSE
The company’s arm received EIR with VAI status for Maryland facility
Jubilant Pharmova’s arm gets EIR with VAI status for Maryland facility
With the receipt of the EIR from the USFDA, the inspection stands successfully closed
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova reports Profit after tax of Rs 53.00 Mln, in the December 2024 quarter
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova’s arm voluntary pays $25 million term loan
The company has prepaid $25 million term loan on January 24, 2025
Jubilant Pharmova informs about board meeting
Jubilant Pharmova informs about disclosure
USFDA completes inspection at Jubilant Pharmova’s arm’s solid oral formulations facility at Salisbury
USFDA has issued five observations with no repeat observations
Jubilant Pharmova informs about board meeting
Jubilant Pharmova informs about outcome of board meeting
Jubilant Pharmova reports Profit after tax of Rs 105.00 Mln, in the September 2024 quarter
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova informs about deletion of tax demand raised on Jubilant Generics
Jubilant Pharmova informs about disclosure
Jubilant Pharmova informs about closure of manufacturing operations
Jubilant Pharmova informs about updates on acquisition
Jubilant Pharmova informs about change in directorate
Jubilant Pharmova informs about analyst meeting
Jubilant Pharmova informs about updates
Jubilant Pharmova informs about updates
Jubilant Pharmova informs about communication
USFDA concludes audit at Jubilant Pharmova’s step down subsidiary’s solid dosage formulations facility
The USFDA has issued 4 observations pursuant to the completion of audit
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova reports Profit after tax of Rs -24.00 Mln, in the December 2023 quarter
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova soars as its arm receives USFDA’s approval for Technetium Sulfur Colloid Injection
For this approval, Jubilant is eligible for 180 days of exclusivity through the ‘Competitive Generic Therapy’ designation from the USFDA
Jubilant Pharmova’s arm receives USFDA’s approval for Technetium Sulfur Colloid Injection
For this approval, Jubilant is eligible for 180 days of exclusivity through the ‘Competitive Generic Therapy’ designation from the USFDA
Jubilant Pharmova informs about newspaper publication
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova reports Profit after tax of Rs -4.00 Mln, in the September 2023 quarter
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova informs about presentation
Jubilant Pharmova reports 87% fall in Q1 consolidated net profit
Total consolidated income of the company increased by 9.06% at Rs 1595.50 crore for Q1FY24
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova reports Profit after tax of Rs 19.00 Mln, in the June 2023 quarter
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova informs about outcome of board meeting
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova reports Profit after tax of Rs -308.60 Mln, in the March 2023 quarter
Jubilant Pharmova’s arm gets additional loan facility from Government of Canada
This expansion project is aimed at upgrading the company’s Montreal facility
Jubilant Pharmova informs about communication
USFDA classifies Jubilant Pharmova’s API Facility as VAI
USFDA had inspected its API manufacturing facility at Nanjangud during December 05, 2022 to December 13, 2022
Jubilant Pharmova informs about appointment of statutory auditors
Jubilant Pharmova reports consolidated net loss of Rs 16 crore in Q3FY23
Total consolidated income of the company increased by 18.65% to Rs 1561.98 crore for Q3FY23
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova informs about investor conference call
Jubilant Pharmova surges as its arm receives USFDA’s approval for Technetium Mertiatide Injection
This approval is effective from January 30, 2023
Jubilant Pharmova’s arm receives USFDA’s approval for Technetium Mertiatide Injection
This approval is effective from January 30, 2023
Jubilant Pharmova informs about credit rating
Jubilant Pharmova informs about closure of trading window
USFDA concludes inspection at Jubilant Pharmova’s API manufacturing facility in Nanjangud
The US FDA has issued eight observations pursuant to the completion of the inspection
Jubilant Pharmova informs about granted stock options
Jubilant Pharmova reports Profit after tax of Rs 918.10 Mln, in the September 2022 quarter
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova soars as its arm gets EIR from USFDA for radiopharmaceuticals manufacturing facility Montreal Canada
With the receipt of the EIR, the inspection stands successfully closed
USFDA completes audit at Jubilant Pharmova’s step down subsidiary’s facility
The USFDA has issued six observations pursuant to the completion of the audit
Jubilant Pharmova informs about outcome of board meeting
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova reports Profit after tax of Rs -51.80 Mln, in the June 2022 quarter
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova - Quaterly Results
Jubilant Pharmova’s arm enters into loan agreement with Standard Chartered Bank
The agreement is for five year loan facility for repayment of existing term loan and bonds aggregating $350 million